{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:45:45Z","timestamp":1794717945305,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67215-4","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T18:03:16Z","timestamp":1766858596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Age-specific clinical performance of HPV-based vs. cytology-based cervical cancer screening in China"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4874-3810","authenticated-orcid":false,"given":"Jian","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0154-7126","authenticated-orcid":false,"given":"Shaokai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinjing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1627-1150","authenticated-orcid":false,"given":"Beihua","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xibin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9294-0005","authenticated-orcid":false,"given":"Fanghui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6380-0871","authenticated-orcid":false,"given":"Youlin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"67215_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"67215_CR2","first-page":"70","volume":"2","author":"X Gu","year":"2022","unstructured":"Gu, X. et al. Incidence and mortality of cervical cancer in China in 2015. J. Natl. Cancer Cent. 2, 70\u201377 (2022).","journal-title":"J. Natl. Cancer Cent."},{"key":"67215_CR3","first-page":"2","volume":"1","author":"S Zhang","year":"2021","unstructured":"Zhang, S. et al. Cancer incidence and mortality in China, 2015. J. Natl. Cancer Cent. 1, 2\u201311 (2021).","journal-title":"J. Natl. Cancer Cent."},{"key":"67215_CR4","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1002\/cncr.30667","volume":"123","author":"W Small Jr.","year":"2017","unstructured":"Small, W. Jr. et al. Cervical cancer: a global health crisis. Cancer 123, 2404\u20132412 (2017).","journal-title":"Cancer"},{"key":"67215_CR5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S0140-6736(18)32849-6","volume":"393","author":"F Zhao","year":"2019","unstructured":"Zhao, F. & Qiao, Y. Cervical cancer prevention in China: a key to cancer control. Lancet 393, 969\u2013970 (2019).","journal-title":"Lancet"},{"key":"67215_CR6","first-page":"1863","volume":"101","author":"YX Zhao","year":"2021","unstructured":"Zhao, Y. X. et al. [Analysis of the reported data of National Cervical Cancer Screening Program in Rural Areas in China from 2009 to 2018]. Zhonghua Yi Xue Za Zhi 101, 1863\u20131868 (2021).","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"67215_CR7","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ijc.21955","volume":"119","author":"J Cuzick","year":"2006","unstructured":"Cuzick, J. et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119, 1095\u20131101 (2006).","journal-title":"Int. J. Cancer"},{"key":"67215_CR8","first-page":"CD008587","volume":"8","author":"G Koliopoulos","year":"2017","unstructured":"Koliopoulos, G. et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst. Rev. 8, CD008587 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"67215_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078641","volume":"386","author":"F Zhao","year":"2024","unstructured":"Zhao, F., Lang, J., Qiao, Y. & Zhu, L. How can China achieve WHO\u2019s 2030 targets for eliminating cervical cancer? BMJ 386, e078641 (2024).","journal-title":"BMJ"},{"key":"67215_CR10","doi-asserted-by":"publisher","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","volume":"30","author":"M Arbyn","year":"2012","unstructured":"Arbyn, M. et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30, F88\u2013F99 (2012).","journal-title":"Vaccine"},{"key":"67215_CR11","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1470-2045(22)00294-7","volume":"23","author":"M Arbyn","year":"2022","unstructured":"Arbyn, M. et al. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis. Lancet Oncol. 23, 950\u2013960 (2022).","journal-title":"Lancet Oncol."},{"key":"67215_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bpobgyn.2020.02.008","volume":"65","author":"N Bhatla","year":"2020","unstructured":"Bhatla, N. & Singhal, S. Primary HPV screening for cervical cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 65, 98\u2013108 (2020).","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"67215_CR13","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","volume":"383","author":"G Ronco","year":"2014","unstructured":"Ronco, G. et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383, 524\u2013532 (2014).","journal-title":"Lancet"},{"key":"67215_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","volume":"136","author":"TC Wright","year":"2015","unstructured":"Wright, T. C. et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol. Oncol. 136, 189\u2013197 (2015).","journal-title":"Gynecol. Oncol."},{"key":"67215_CR15","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/S0140-6736(07)61450-0","volume":"370","author":"NW Bulkmans","year":"2007","unstructured":"Bulkmans, N. W. et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370, 1764\u20131772 (2007).","journal-title":"Lancet"},{"key":"67215_CR16","unstructured":"World Health Organization. Reaching 2030 cervical cancer elimination targets\u2014new WHO recommendations for screening and treatment of cervical pre-cancer. Available from: https:\/\/www.who.int\/news-room\/events\/detail\/2021\/07\/06\/default-calendar\/reaching-2030-cervical-cancer-elimination-targets. Accessed 6 July 2021."},{"key":"67215_CR17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.cmi.2021.04.031","volume":"27","author":"M Arbyn","year":"2021","unstructured":"Arbyn, M. et al. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin. Microbiol. Infect. 27, 1083\u20131095 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"67215_CR18","unstructured":"Center for Medical Device Evaluation. NMPA. Guidelines for the technical review of human papillomavirus (HPV) nucleic acid detection and genotyping reagents. Available from: https:\/\/www.cmde.org.cn\/\/flfg\/zdyz\/zdyzwbk\/20170405151300482.html. Accessed 5 April 2015."},{"key":"67215_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-96","volume":"14","author":"LN Kang","year":"2014","unstructured":"Kang, L. N. et al. A prospective study of age trends of high-risk human papillomavirus infection in rural China. BMC Infect. Dis. 14, 96 (2014).","journal-title":"BMC Infect. Dis."},{"key":"67215_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12905-024-02904-8","volume":"24","author":"X Yin","year":"2024","unstructured":"Yin, X. et al. HPV prevalence and distribution characteristics in postmenopausal women from Nanjing, China. BMC Women\u2019s Health 24, 68 (2024).","journal-title":"BMC Women\u2019s Health"},{"key":"67215_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-03975-6","volume":"23","author":"S Han","year":"2025","unstructured":"Han, S. et al. Prevalence, trends, and geographic distribution of human papillomavirus infection in Chinese women: a summative analysis of 2,728,321 cases. BMC Med. 23, 158 (2025).","journal-title":"BMC Med"},{"key":"67215_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0299651","volume":"19","author":"B Yao","year":"2024","unstructured":"Yao, B. et al. Real-world effectiveness of cytology and HPV-based screening strategy in cervical cancer screening: a cross-sectional population-based study in Chengdu, China. PLoS ONE 19, e0299651 (2024).","journal-title":"PLoS ONE"},{"key":"67215_CR23","doi-asserted-by":"publisher","first-page":"413","DOI":"10.46234\/ccdcw2024.080","volume":"6","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Estimated human papillomavirus vaccine coverage among females 9-45 years of age\u2014China, 2017-2022. China CDC Wkly 6, 413\u2013417 (2024).","journal-title":"China CDC Wkly"},{"key":"67215_CR24","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.46234\/ccdcw2022.217","volume":"4","author":"M Zhang","year":"2022","unstructured":"Zhang, M. et al. Cervical Cancer Screening Coverage - China, 2018-2019. China CDC Wkly. 4, 1077\u20131082 (2022).","journal-title":"China CDC Wkly."},{"key":"67215_CR25","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1158\/1055-9965.EPI-10-0645","volume":"19","author":"P Gonzalez","year":"2010","unstructured":"Gonzalez, P. et al. Behavioral\/lifestyle and immunologic factors associated with HPV infection among women older than 45 years. Cancer Epidemiol. Biomark. Prev. 19, 3044\u20133054 (2010).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"67215_CR26","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jama.288.14.1749","volume":"288","author":"SL Kulasingam","year":"2002","unstructured":"Kulasingam, S. L. et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288, 1749\u20131757 (2002).","journal-title":"JAMA"},{"key":"67215_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ygyno.2016.04.027","volume":"142","author":"K Chatzistamatiou","year":"2016","unstructured":"Chatzistamatiou, K., Moysiadis, T., Moschaki, V., Panteleris, N. & Agorastos, T. Comparison of cytology, HPV DNA testing and HPV 16\/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening. Gynecol. Oncol. 142, 120\u2013127 (2016).","journal-title":"Gynecol. Oncol."},{"key":"67215_CR28","doi-asserted-by":"publisher","first-page":"e1915781","DOI":"10.1001\/jamanetworkopen.2019.15781","volume":"2","author":"L Torres-Ibarra","year":"2019","unstructured":"Torres-Ibarra, L. et al. Comparison of HPV-16 and HPV-18 genotyping and cytological testing as triage testing within human papillomavirus-based screening in Mexico. JAMA Netw. Open 2, e1915781 (2019).","journal-title":"JAMA Netw. Open"},{"key":"67215_CR29","doi-asserted-by":"publisher","first-page":"184 e181","DOI":"10.1016\/j.ajog.2012.11.020","volume":"208","author":"JT Cox","year":"2013","unstructured":"Cox, J. T. et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16\/18: results from the ATHENA HPV study. Am. J. Obstet. Gynecol. 208, 184 e181\u2013184.e111 (2013).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"67215_CR30","doi-asserted-by":"crossref","unstructured":"Ostrbenk Valencak, A. et al. Clinically validated HPV assays offer comparable long-term safety in primary cervical cancer screening: a 9-year follow-up of a population-based screening cohort. Int. J. Cancer 156, 788\u2013801 (2025).","DOI":"10.1002\/ijc.35200"},{"key":"67215_CR31","doi-asserted-by":"publisher","first-page":"a1754","DOI":"10.1136\/bmj.a1754","volume":"337","author":"J Dillner","year":"2008","unstructured":"Dillner, J. et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337, a1754 (2008).","journal-title":"BMJ"},{"key":"67215_CR32","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/jnci\/djn065","volume":"100","author":"G Ronco","year":"2008","unstructured":"Ronco, G. et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl. Cancer Inst. 100, 492\u2013501 (2008).","journal-title":"J. Natl. Cancer Inst."},{"key":"67215_CR33","doi-asserted-by":"crossref","unstructured":"Safaeian, M., Solomon, D. & Castle, P. E. Cervical cancer prevention\u2014cervical screening: science in evolution. Obstet. Gynecol. Clin. North Am. 34, 739\u2013760, ix (2007).","DOI":"10.1016\/j.ogc.2007.09.004"},{"key":"67215_CR34","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/GME.0000000000002546","volume":"32","author":"Q Zhou","year":"2025","unstructured":"Zhou, Q. et al. The clinical performance of different cervical cancer screening strategies in premenopausal and postmenopausal women. Menopause 32, 640\u2013647 (2025).","journal-title":"Menopause"},{"key":"67215_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/ijc.31326","volume":"143","author":"A Del Mistro","year":"2018","unstructured":"Del Mistro, A. et al. Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more. Int. J. Cancer 143, 333\u2013342 (2018).","journal-title":"Int. J. Cancer"},{"key":"67215_CR36","doi-asserted-by":"publisher","first-page":"14794","DOI":"10.1002\/cam4.6109","volume":"12","author":"A Bai","year":"2023","unstructured":"Bai, A., Xue, P., Li, Q., Jiang, Y. & Qiao, Y. Diagnostic value of high-risk HPV other than type 16\/18 in high-grade cervical neoplasia among cytology-negative women: a multicenter retrospective study. Cancer Med. 12, 14794\u201314805 (2023).","journal-title":"Cancer Med."},{"key":"67215_CR37","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1002\/ijc.30375","volume":"139","author":"M Schiffman","year":"2016","unstructured":"Schiffman, M. et al. A cohort study of cervical screening using partial HPV typing and cytology triage. Int. J. Cancer 139, 2606\u20132615 (2016).","journal-title":"Int. J. Cancer"},{"key":"67215_CR38","doi-asserted-by":"publisher","first-page":"e0119755","DOI":"10.1371\/journal.pone.0119755","volume":"10","author":"T Agorastos","year":"2015","unstructured":"Agorastos, T. et al. Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology. PLoS ONE 10, e0119755 (2015).","journal-title":"PLoS ONE"},{"key":"67215_CR39","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/ijc.31261","volume":"143","author":"K Cuschieri","year":"2018","unstructured":"Cuschieri, K. et al. Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs. Int. J. Cancer 143, 735\u2013745 (2018).","journal-title":"Int. J. Cancer"},{"key":"67215_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","volume":"70","author":"KA Workowski","year":"2021","unstructured":"Workowski, K. A. et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm. Rep. 70, 1\u2013187 (2021).","journal-title":"MMWR Recomm. Rep."},{"key":"67215_CR41","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/ijc.35036","volume":"155","author":"C Lobin","year":"2024","unstructured":"Lobin, C. et al. Cost-effectiveness analysis of alternative screening strategies for the detection of cervical cancer among women in rural areas of Western Kenya. Int. J. Cancer 155, 1257\u20131267 (2024).","journal-title":"Int. J. Cancer"},{"key":"67215_CR42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/ijc.24717","volume":"126","author":"A Chao","year":"2010","unstructured":"Chao, A. et al. Incidence and outcome of acquisition of human papillomavirus infection in women with normal cytology\u2014a population-based cohort study from Taiwan. Int. J. Cancer 126, 191\u2013198 (2010).","journal-title":"Int. J. Cancer"},{"key":"67215_CR43","doi-asserted-by":"crossref","unstructured":"Xu, L., Ostrbenk Valencak, A., Poljak, M. & Arbyn, M. Evaluation and optimization of the clinical accuracy of Hybribio\u2019s 14 high-risk HPV with 16\/18 genotyping assay within the VALGENT-3 Framework. J. Clin. Microbiol. 58, e00234-20 (2020).","DOI":"10.1128\/JCM.00234-20"},{"key":"67215_CR44","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.cmi.2018.02.027","volume":"24","author":"X Zhao","year":"2018","unstructured":"Zhao, X. et al. The performance of human papillomavirus DNA detection with type 16\/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women. Clin. Microbiol. Infect. 24, 1322\u20131327 (2018).","journal-title":"Clin. Microbiol. Infect."},{"key":"67215_CR45","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01570-21","volume":"10","author":"Y Fu","year":"2022","unstructured":"Fu, Y. et al. Head-to-head comparison of DH3 HPV test and HC2 Assay for detection of high-risk HPV infection in residual cytology samples from cervical cancer screening setting: baseline and 3-year longitudinal data. Microbiol. Spectr. 10, e0157021 (2022).","journal-title":"Microbiol. Spectr."},{"key":"67215_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jcv.2016.12.004","volume":"87","author":"DA Cook","year":"2017","unstructured":"Cook, D. A. et al. Aptima HPV Assay versus Hybrid Capture((R)) 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial. J. Clin. Virol. 87, 23\u201329 (2017).","journal-title":"J. Clin. Virol."},{"key":"67215_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1161631","volume":"13","author":"F Zhong","year":"2023","unstructured":"Zhong, F. et al. HPV genotyping of cervical histologic specimens of 61,422 patients from the largest women hospital in China. Front. Oncol. 13, 1161631 (2023).","journal-title":"Front. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67215-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67215-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67215-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:06:14Z","timestamp":1768403174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67215-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67215"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67215-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"11 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"521"}}